Literature DB >> 10638400

Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. Italian Collaborative Study Group on the Outcome of Severe Mental Disorders.

G Tognoni1.   

Abstract

OBJECTIVE: To describe the epidemiology of psychotropic drug use in a sample of Italian outpatient psychiatric services.
METHODS: Drug-utilisation survey conducted within the framework of a broader prospective follow-up study with 67 Italian outpatient psychiatric services.
RESULTS: The data concern 2322 patients recruited over a 3-year period. Three-quarters of the cohort were prescribed antipsychotic drugs, one-half received benzodiazepines and nearly one-third received antidepressants. The trends in drug use from 1994 to 1997 show that for patients with schizophrenia there has been a decrease in the prescription of typical neuroleptics: the use of haloperidol passed from 56% to 42.4% and that of chlorpromazine dropped from 13.5% to 6.1%; during the same period, an increasing use of the atypical compound risperidone was observed. Among patients suffering from unipolar affective psychosis, the prescriptions of tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) have not changed in time, while the proportion of patients receiving neuroleptic drugs has increased from 41% to 45.2%. In addition, the use of antiepileptic drugs and lithium increased, irrespective of diagnosis. Almost 40% of the patients on psychotropic drugs received three or more drugs. Finally, a positive association was found between the number of prescribed compounds and the daily dose administered.
CONCLUSION: These data indicate that in the absence of a rational approach to drug use, a symptomatic approach is generally adopted, by which common sense, experience, information provided by non-independent agencies and other cultural parameters play an important role in the prescription strategy. Pharmacoepidemiology should more often consider the use of drugs as a dependent variable, to be investigated within the context of other clinical, cultural, social and setting-related parameters; this approach would enable a more comprehensive assessment of prescribing practices and strategies in routine clinical care.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10638400     DOI: 10.1007/s002280050694

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia.

Authors:  Kang Sim; Alex Su; Senta Fujii; Shu-Yu Yang; Mian-Yoon Chong; Gabor S Ungvari; Tianmei Si; Eun K Chung; Hin-Yeung Tsang; Yiong H Chan; Stephan Heckers; Naotaka Shinfuku; Chay H Tan
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

2.  Drug treatment modalities in psychiatric inpatient practice: a 20-year comparison.

Authors:  Corrado Barbui; Arcangelo Ciuna; Michela Nosè; Deborah Levi; Margherita Andretta; Scott B Patten; Francesco Amaddeo; Michele Tansella
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-19       Impact factor: 5.270

Review 3.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

Review 4.  The current state of mental health care in Italy: problems, perspectives, and lessons to learn.

Authors:  Giovanni de Girolamo; Mariano Bassi; Giovanni Neri; Mirella Ruggeri; Giovanni Santone; Angelo Picardi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-03       Impact factor: 5.270

5.  Safety and tolerability of antipsychotic polypharmacy.

Authors:  Juan A Gallego; Jimmi Nielsen; Marc De Hert; John M Kane; Christoph U Correll
Journal:  Expert Opin Drug Saf       Date:  2012-05-08       Impact factor: 4.250

Review 6.  Patient compliance with drug therapy in schizophrenia. Economic and clinical issues.

Authors:  E Lindström; K Bingefors
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

7.  Prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey.

Authors:  Lorenza Magliano; Andrea Fiorillo; Manuela Guarneri; Cecilia Marasco; Corrado De Rosa; Claudio Malangone; Mario Maj
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

8.  High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies.

Authors:  Kang Sim; Hsin Chuan Su; Senta Fujii; Shu-Yu Yang; Mian-Yoon Chong; Gabor Ungvari; Tianmei Si; Yan Ling He; Eun Kee Chung; Yiong Huak Chan; Naotaka Shinfuku; Ee Heok Kua; Chay Hoon Tan; Norman Sartorius
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

Review 9.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Authors:  Christoph U Correll; Juan A Gallego
Journal:  Psychiatr Clin North Am       Date:  2012-07-24

10.  Use of antipsychotic and antidepressant within the Psychiatric Disease Centre, Regional Health Service of Ferrara.

Authors:  Stefano Bianchi; Erica Bianchini; Paola Scanavacca
Journal:  BMC Clin Pharmacol       Date:  2011-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.